GSK and Ochre Bio enter multi-year partnership to investigate liver disease drivers

2024-06-13

引进/卖出快速通道寡核苷酸临床研究

GSK and Ochre Bio enter multi-year partnership to investigate liver disease drivers

Preview

来源: PMLiVE

GSK has entered into a multi-year data licence agreement with Ochre Bio to investigate the drivers of liver disease and accelerate the development of therapeutics, with the deal worth up to $37.5m.

The partnership gives GSK access to Ochre’s computational biology, cellular and perfused human organ platforms to generate proprietary human liver data sets, as well as non-exclusive access to its library of historical liver data.

The companies have not specified what indications they will target, but both will use the data to build artificial intelligence (AI) models that allow for more precise experiments to aid in target choice.

Kim Branson, senior vice president, global head of AI and machine learning at GSK, said: “Ochre Bio’s platform will provide GSK with foundational data sets to create AI models, allowing us to better understand liver function and disease for the development of novel medicines.”

The agreement has a total value of up to $37.5m for both co-exclusive and non-exclusive data licences.

Jack O’Meara, Ochre’s co-founder and chief executive officer, said: “Data innovation is as important as algorithmic innovation when investing in machine learning workflows… These large-scale, causal human data sets will be foundational for our respective liver research and development pipelines.”

Liver disease, including metabolic dysfunction-associated steatohepatitis (MASH), primary biliary cholangitis and hepatitis B, results in more than 10,000 UK deaths every year.

GSK’s investigational antisense oligonucleotide bepirovirsen was granted fast track designation from the US Food and Drug Administration in February as a treatment for chronic hepatitis B, which affects nearly 300 million people worldwide.

“In addition to our programmes in MASH to hepatitis B, we are committed to addressing unmet needs in liver disease by generating unique data in human derived systems,” Branson said in the latest announcement.